Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

Trial Profile

A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blonanserin (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma
  • Most Recent Events

    • 27 Sep 2013 Based on positive results in this trial, an application for registration of blonanserin for the treatment of schizophrenia has been submitted in China, according to a Dainippon Sumitomo Pharma media release.
    • 14 Nov 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 14 Nov 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top